• Shufeng Xingbi Therapy Modulates Immunity and Gut Flora in A

  2026-05-27

  This study investigates Shufeng Xingbi Therapy's (SFXBT) impact on Th1/Th2 immune balance and intestinal microbiota in a rat model of allergic rhinitis (AR). The research demonstrates that SFXBT can attenuate nasal inflammation, shift immune responses, and remodel gut microbial communities, providing mechanistic insights relevant for immunology and microbiome research.

• ATP2A2 as a Druggable Co-regulator of Cyclin D1 in Lung Aden

  2026-05-27

  A recent membrane protein-focused CRISPR screen identified ATP2A2 as a key transcriptional co-regulator of CCND1 (cyclin D1) in lung adenocarcinoma. This work uncovers the ATP2A2-HACD3-NF-κB-CCND1 signaling axis as a potential therapeutic target, providing new insight into cell cycle regulation and resistance mechanisms in non-small cell lung cancer.

• Shufeng Xingbi Therapy Restores Immune Balance in AR Rats

  2026-05-26

  This study investigates how Shufeng Xingbi Therapy modulates Th1/Th2 immune balance and the gut microbiota in a rat model of allergic rhinitis. The findings highlight a significant reduction in nasal inflammation, serum IgE, and IL-4, with simultaneous shifts in intestinal bacterial composition and increased short-chain fatty acids, suggesting a microbiota-immune axis as a therapeutic target.

• Eicosapentaenoic Acid for Cardiovascular and Immunity Resear

  2026-05-26

  Eicosapentaenoic Acid (EPA) empowers labs with robust lipid-lowering, anti-inflammatory, and membrane-modulating activities, making it invaluable for cardiovascular and immunology studies. This article delivers actionable protocols, troubleshooting strategies, and cross-domain insights, revealing how EPA from APExBIO advances reproducibility and innovation at the bench.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-05-25

  This study identifies sterol O-acyltransferase 1 (SOAT1) as a central driver of foam cell formation and lipophagy impairment in polyhexamethylene guanidine (PHMG)-induced pulmonary fibrosis. Targeting SOAT1 with avasimibe reverses cholesterol dysregulation and attenuates fibrotic progression, suggesting new therapeutic strategies for environmental lung injury.

• Cyclo (-RGDfC) in High-Throughput Tumor Targeting Assays

  2026-05-25

  Cyclo (-RGDfC) empowers precise, scalable integrin αvβ3 targeting in cancer and angiogenesis research. Discover how this cyclic peptide transforms high-throughput hydrogel workflows and cell adhesion assays with unmatched specificity and reproducibility.

• SU5416 (Semaxanib): Precision Angiogenesis Inhibition in Res

  2026-05-24

  SU5416 (Semaxanib) delivers robust and selective VEGFR2 inhibition for dissecting angiogenesis in cancer, vascular, and immune research models. Its dual role as a small molecule angiogenesis inhibitor and immune modulator sets new standards for reproducibility and translational depth, especially when leveraged using APExBIO's validated protocols.

• Miltefosine: Advancing Neutrophil Differentiation in Leukope

  2026-05-23

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) delivers dual-action modulation of PI3K/Akt and Ras/MEK/ERK pathways, enabling precise control of neutrophil differentiation and bone marrow recovery. This article details actionable protocols, advanced troubleshooting, and new mechanistic insights that set Miltefosine apart for hematology and oncology research.

• Dihydroethidium (DHE): Reliable Superoxide Measurement in Ce

  2026-05-22

  This article provides an evidence-based, scenario-driven guide to overcoming common pitfalls in oxidative stress detection using Dihydroethidium (DHE, SKU C3807). From conceptual principles to vendor selection, we address workflow challenges and showcase how high-purity DHE from APExBIO ensures reproducibility, sensitivity, and data fidelity for intracellular reactive oxygen species assays.

• Dual FOXO3-Mediated Metabolic Inhibition in Hepatocellular C

  2026-05-22

  This study uncovers how activation of FOXO3 transcriptionally represses YAP, resulting in simultaneous inhibition of glycolysis and glutaminolysis in hepatocellular carcinoma (HCC). The findings reveal a critical metabolic vulnerability and propose the FOXO3/YAP axis as a promising therapeutic target in HCC.

• Bacillus Strains and Media Shape γ-Glutamyl Peptide Producti

  2026-05-21

  This study systematically evaluates how Bacillus strain selection and growth medium composition affect the generation of γ-glutamyl peptides, including key dipeptides and glutathione. The findings reveal that medium composition has a stronger influence than strain type, with implications for both food biotechnology and glutathione metabolism research.

• MLN2238: Precision Proteasome β5 Subunit Inhibitor Workflows

  2026-05-21

  MLN2238 sets a new benchmark for chymotrypsin-like proteasome inhibition, enabling robust workflows in oncology and proteostasis research. Explore step-by-step protocols, troubleshooting tactics, and translational insights from the latest reference study to maximize assay success and drive discoveries in drug resistance and neurodegeneration.

• SU5416 (Semaxanib): Applied Protocols for Angiogenesis Inhib

  2026-05-20

  SU5416 (Semaxanib) is a validated, selective VEGFR2 inhibitor that empowers researchers to precisely dissect angiogenesis and immune modulation in cancer, vascular, and immunological models. This guide delivers stepwise protocol enhancements, troubleshooting strategies, and translational context—bridging key findings from biomarker-driven PAH research to optimized experimental workflows.

• Neticonazole Hydrochloride: Dual-Action Imidazole Antifungal

  2026-05-20

  Neticonazole Hydrochloride uniquely bridges antifungal and oncology research, enabling streamlined experimental protocols for both fungal inhibition and colorectal cancer models. Its dual mechanisms and robust solubility empower reliable workflows, while recent advances in nanoparticle delivery position it at the forefront of translational therapeutics.

• L1023 Anti-Cancer Compound Library: Streamlining High-Throug

  2026-05-19

  The L1023 Anti-Cancer Compound Library empowers researchers with 1164 curated, bioactive molecules for rapid, pathway-centric cancer drug discovery. Its high-throughput-ready format and proven selectivity accelerate experimental workflows, supporting innovative screening strategies and robust troubleshooting in cancer research.

16255 records 1/1084 page Next 12345 下5页 Last page